Hormone receptor-positive early breast cancer in young women: A comprehensive review

IF 11.3 1区化学 Q1 CHEMISTRY, PHYSICAL

ACS Catalysis Pub Date : 2024-07-14 DOI:10.1016/j.ctrv.2024.102804

Benjamin Walbaum , Isabel García-Fructuoso , Olga Martínez-Sáez , Francesco Schettini , César Sánchez , Francisco Acevedo , Nuria Chic , Javier Muñoz-Carrillo , Barbara Adamo , Montserrat Muñoz , Ann H. Partridge , Meritxell Bellet , Fara Brasó-Maristany , Aleix Prat , Maria Vidal

{"title":"Hormone receptor-positive early breast cancer in young women: A comprehensive review","authors":"Benjamin Walbaum , Isabel García-Fructuoso , Olga Martínez-Sáez , Francesco Schettini , César Sánchez , Francisco Acevedo , Nuria Chic , Javier Muñoz-Carrillo , Barbara Adamo , Montserrat Muñoz , Ann H. Partridge , Meritxell Bellet , Fara Brasó-Maristany , Aleix Prat , Maria Vidal","doi":"10.1016/j.ctrv.2024.102804","DOIUrl":null,"url":null,"abstract":"<div><p>The incidence of breast cancer in ≤ 40 yr-old women (YWBC) has been steadily increasing in recent decades. Although this group of patients represents less than 10 % of all newly diagnosed BC cases it encompasses a significant burden of disease. Usually underrepresented in clinical trials, YWBCs are also characterized by late diagnoses and poorly differentiated, aggressive-subtype disease, partly explaining its poor prognosis along with a high recurrence risk, and high mortality rates. On the other hand, YWBC treatment poses unique challenges such as preservation of fertility, and long-term toxicity and adverse events. Herein, we summarize the current evidence in hormone receptor-positive YWBC including specific risk factors, clinicopathologic and genomic features, and available evidence on response to chemotherapy and endocrine therapy. Overall, we advocate for a more comprehensive multidisciplinary healthcare model to improve the outcomes and the quality of life of this subset of younger patients.</p></div>","PeriodicalId":9,"journal":{"name":"ACS Catalysis ","volume":null,"pages":null},"PeriodicalIF":11.3000,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Catalysis ","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0305737224001324","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

Abstract

The incidence of breast cancer in ≤ 40 yr-old women (YWBC) has been steadily increasing in recent decades. Although this group of patients represents less than 10 % of all newly diagnosed BC cases it encompasses a significant burden of disease. Usually underrepresented in clinical trials, YWBCs are also characterized by late diagnoses and poorly differentiated, aggressive-subtype disease, partly explaining its poor prognosis along with a high recurrence risk, and high mortality rates. On the other hand, YWBC treatment poses unique challenges such as preservation of fertility, and long-term toxicity and adverse events. Herein, we summarize the current evidence in hormone receptor-positive YWBC including specific risk factors, clinicopathologic and genomic features, and available evidence on response to chemotherapy and endocrine therapy. Overall, we advocate for a more comprehensive multidisciplinary healthcare model to improve the outcomes and the quality of life of this subset of younger patients.

查看原文本刊更多论文

年轻女性中激素受体阳性的早期乳腺癌：综述

近几十年来，40 岁以下女性（YWBC）的乳腺癌发病率一直在稳步上升。虽然这部分患者在所有新确诊的乳腺癌病例中占比不到 10%，但却造成了巨大的疾病负担。YWBC 通常在临床试验中代表性不足，其特点还包括诊断晚、分化差、侵袭性亚型疾病，这也是其预后差、复发风险高和死亡率高的部分原因。另一方面，YWBC 的治疗也面临着独特的挑战，如保留生育能力、长期毒性和不良反应等。在此，我们总结了激素受体阳性 YWBC 的现有证据，包括特定的风险因素、临床病理和基因组特征，以及化疗和内分泌治疗反应的现有证据。总之，我们主张采用更全面的多学科医疗保健模式来改善这一年轻患者群体的治疗效果和生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Catalysis CHEMISTRY, PHYSICAL-

CiteScore

20.80

自引率

6.20%

发文量

1253

审稿时长

1.5 months

期刊介绍： ACS Catalysis is an esteemed journal that publishes original research in the fields of heterogeneous catalysis, molecular catalysis, and biocatalysis. It offers broad coverage across diverse areas such as life sciences, organometallics and synthesis, photochemistry and electrochemistry, drug discovery and synthesis, materials science, environmental protection, polymer discovery and synthesis, and energy and fuels. The scope of the journal is to showcase innovative work in various aspects of catalysis. This includes new reactions and novel synthetic approaches utilizing known catalysts, the discovery or modification of new catalysts, elucidation of catalytic mechanisms through cutting-edge investigations, practical enhancements of existing processes, as well as conceptual advances in the field. Contributions to ACS Catalysis can encompass both experimental and theoretical research focused on catalytic molecules, macromolecules, and materials that exhibit catalytic turnover.